How to Appeal a Medicare Part D Formulary Exclusion in 2026: Exceptions, the 72-Hour Clock, and the Five-Level Appeal Path

You hand the pharmacist your prescription and the screen reads "not covered." A minute later they hand it back with a print-out that says the drug is not on your plan's formulary, or the drug is subject to prior authorization, or your out-of-pocket cost is $842. That's a Part D coverage denial in one of its forms, and in 2026 it is one of the most winnable disputes in Medicare — provided you file the right kind of exception, hit the 72-hour clock, and get your prescriber to write the supporting statement the plan actually needs.

This is the 2026 playbook: which type of exception fits your situation, how fast the plan has to decide, what the $2,100 out-of-pocket cap does and doesn't cover, the five-level appeal ladder from plan redetermination to federal court, and the specific paths that work when appeal is not an option because the drug is excluded from Part D by statute rather than by the plan.

Medicare Part D uses two different words for two different things, and confusing them costs people time on the clock.

A coverage determination is the first decision your plan makes about whether it will pay for a specific drug for you. If the pharmacy tells you the drug is not covered, or the plan's rules will not let it be filled the way it was prescribed, you (or your prescriber) can request a coverage determination in writing. Two of the most common types of coverage determination are exceptions:

• Formulary exception: a request that the plan cover a drug that isn't on its formulary, or waive a utilization rule (prior authorization, step therapy, or a quantity limit) on a drug that is on the formulary.
• Tiering exception: a request that the plan charge you a lower tier's cost-sharing for a covered drug that sits on a higher tier.

An appeal is what happens after a coverage determination goes against you. There are five appeal levels, described below.

The type of exception decides both what your prescriber has to say and what the plan is allowed to weigh in its decision.

Situation 1: Your drug is not on the formulary at all

File a formulary exception. Your prescriber must submit a supporting statement that the alternatives on the plan's formulary would not be as effective for treating your condition, would cause an adverse reaction, or are otherwise clinically inappropriate for you. The statement must name specific alternatives, not just say the requested drug is medically necessary.

Situation 2: Your drug is on the formulary but subject to prior authorization, step therapy, or a quantity limit

File a formulary exception asking the plan to waive the specific utilization rule. For step therapy the prescriber typically has to show that you have already tried and failed the required earlier drugs, or that they are contraindicated for your condition. For a quantity limit exception the prescriber has to justify the higher dose or greater number of units clinically.

Situation 3: Your drug is on the formulary but on a higher tier than you can afford

File a tiering exception. The prescriber has to certify that the lower-tier alternatives would be less effective, cause an adverse reaction, or otherwise be medically inappropriate. Successful tiering exceptions move your cost-sharing to the lower tier for the plan year.

Once your request and the prescriber's supporting statement reach the plan, the clock starts.

Standard coverage determination: 72 hours

The plan has 72 hours from the moment it receives the prescriber's supporting statement to issue a decision. If it does not, the plan is deemed to have granted the request and you can escalate directly to the Independent Review Entity.

Expedited coverage determination: 24 hours

You can request an expedited decision if waiting the standard 72 hours could seriously jeopardize your life, your health, or your ability to regain maximum function. Your prescriber's certification of that clinical urgency shifts the deadline to 24 hours. Plans routinely miss this shorter clock, and the same "deemed granted" rule applies.

The exception form your plan supplies is largely a coversheet. What the plan reviewer reads is the prescriber's supporting statement. A statement built around three elements survives clinical review more often than one that does not.

1. The clinical rationale, named alternative by named alternative. If the plan's formulary offers atorvastatin and pravastatin at Tier 1 and you need rosuvastatin at Tier 3, the statement has to explain, for each specific Tier 1 or Tier 2 alternative, the reason it is not appropriate for this patient — a documented adverse reaction, a specific contraindication, a documented failure to reach the therapeutic goal at a titrated dose, or a specific drug interaction with an existing medication.
2. The medical record backing up each point. Prescribers who cite chart entries and lab values in the statement itself get first-pass approvals more often than prescribers who make general assertions. If a prior trial of the preferred drug failed on a specific date, the statement should reference the visit date and the finding.
3. The exact ask. "Approve rosuvastatin 20 mg daily, 30-day supply, formulary exception at Tier 2 cost-sharing" is a request the plan can process. "Please cover Crestor" is not.

Most prescribers' offices have a template. It's worth asking the office to customize the template to your specific situation before sending it, because generic language is what most first-round denials cite.

If the plan denies the exception, the appeal ladder begins. Each level has its own filing window and decision timeframe. The dollar thresholds at Levels 3 and 5 change annually with inflation.

Thresholds and timeframes reflect Medicare rules in effect for 2026. Dollar thresholds at Levels 3 and 5 are updated by CMS each year.

Most Part D denials that will be reversed at all are reversed at Level 1 or Level 2. If you have already spent your energy on a strong prescriber statement, the redetermination and IRE reconsideration are largely a rerun of that same argument in front of fresh reviewers. Levels 3 through 5 are rare and typically involve either a novel legal question or a very expensive drug where the amount in controversy justifies the effort.

Some drugs are excluded from Part D coverage by federal statute rather than by any plan decision. No exception or appeal can reverse a statutory exclusion, because the plan is not the one saying no — the underlying Medicare law is. The historical statutory exclusion list includes:

• Drugs used for cosmetic purposes or hair growth.
• Prescription vitamins and minerals (with limited exceptions such as prenatal vitamins and fluoride preparations).
• Non-prescription (over-the-counter) drugs.
• Drugs already covered under Medicare Part A or Part B.
• Historically, drugs used for weight loss or weight gain, though CMS policy in this category has been in flux.

If your denied drug falls under a statutory exclusion, the appeal ladder is not the tool. The alternatives are a manufacturer patient assistance program, direct-from-manufacturer cash-pay programs, a discount card, or paying out of pocket. If you have HSA-qualified coverage (uncommon on Medicare but possible before Medicare enrollment), those payments qualify for HSA reimbursement.

Under the Inflation Reduction Act as implemented in 2026, Medicare Part D includes a $2,100 annual out-of-pocket cap. Once your true out-of-pocket spending on covered Part D drugs hits $2,100, you owe $0 on covered prescriptions for the rest of the calendar year. But that cap has a boundary that catches people mid-appeal.

The cap counts only your cost-sharing for drugs the plan covers. Spending on a drug the plan has denied does not accrue toward the cap. If your plan has excluded a drug from its formulary and you are paying $842 a month cash, that $842 is not a step toward the cap — it's a step outside the covered-benefit system entirely. Winning an exception is what pulls your spending back inside the covered-benefit system and, from that point, lets it accrue toward the cap.

The takeaway is that appeals are not just about winning coverage of one drug; on multi-drug regimens they are what determines how quickly the cap protects you overall.

1. At the pharmacy counter: Ask for the printout that says why the claim was rejected. That paper has the rejection code you'll need for the exception request. Ask the pharmacist whether an alternative on your formulary would work in the meantime; many are willing to call your prescriber for you.
2. Same day or next day: Call your Part D plan and request the coverage determination form and the plan's clinical policy for the drug. Ask specifically whether an expedited (24-hour) request applies to your situation.
3. Within 48-72 hours: Get the prescriber to submit the exception request with a supporting statement that names each formulary alternative by name and explains why each one is clinically inappropriate. If clinically justified, ask them to attest to the urgency that triggers the 24-hour clock.
4. Watch the decision window: 24 hours for expedited, 72 hours for standard. If the plan misses the deadline, escalate immediately — the plan is deemed to have granted the request.
5. If denied: The plan's written denial starts a 60-day clock for a Level 1 redetermination. Ask for the specific clinical criteria the plan applied. Have the prescriber cite each criterion by number in the redetermination.
6. If redetermination is denied: File an IRE reconsideration within 60 days. Attach all previous documentation plus any new clinical evidence, particularly documented outcomes on any interim medication.
7. Only if the drug's amount in controversy exceeds $200: Consider a Level 3 ALJ hearing. For most patients on most drugs, the case is either won by IRE or dropped.
8. Alongside all of the above: Enroll in the manufacturer's patient assistance program while the appeal runs. The programs typically pause payment when insurance kicks in, but bridge cover while you're appealing.

The 2027 Medicare Annual Election Period runs October 15 through December 7, 2026. This is the once-a-year window to move to a plan whose formulary already covers your drugs at cost-sharing you can afford — and it's the most efficient reversal of a Part D denial there is, because a different plan design does not require any prescriber statements, appeals, or wait times.

Before AEP starts, pull your Annual Notice of Change from your current plan and cross-check every drug on your current regimen against the 2027 formularies of the plans available in your county. The Medicare Plan Finder at medicare.gov will do this cross-check automatically once you enter your drug list. If your denied drug appears on another plan's formulary at a tier you can afford, switching plans at AEP is the cleanest fix.

Ask for the pharmacy rejection paperwork. File the right kind of exception — formulary if the drug isn't covered or has a utilization rule you need waived, tiering if it's on the formulary at a tier you can't afford. Have the prescriber write a specific supporting statement that names alternatives and explains why each one won't work, and, if clinically justified, attest to the urgency that triggers the 24-hour clock. If the plan misses its decision window, escalate. If the plan denies, use the 60-day windows to move up the appeal ladder through redetermination and IRE reconsideration. And in parallel, use AEP to switch to a 2027 plan whose formulary already covers what you need. Most Part D denials that will ever be reversed are reversed in the first two steps of that path, and the ones that aren't are often better solved by a plan change than by a Level 3 appeal.